Baker BROS. Advisors LP Boosts Position in Design Therapeutics, Inc. $DSGN

Baker BROS. Advisors LP raised its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 30.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,233,099 shares of the company’s stock after acquiring an additional 520,217 shares during the quarter. Baker BROS. Advisors LP owned approximately 3.92% of Design Therapeutics worth $20,946,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of DSGN. Woodline Partners LP bought a new stake in Design Therapeutics during the 1st quarter valued at approximately $2,492,000. Jane Street Group LLC bought a new stake in Design Therapeutics during the 1st quarter valued at approximately $70,000. Strs Ohio bought a new stake in Design Therapeutics during the 1st quarter valued at approximately $87,000. Geode Capital Management LLC boosted its position in Design Therapeutics by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 794,008 shares of the company’s stock valued at $2,676,000 after acquiring an additional 18,511 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Design Therapeutics by 26.8% during the 2nd quarter. Invesco Ltd. now owns 14,364 shares of the company’s stock valued at $48,000 after acquiring an additional 3,033 shares in the last quarter. 56.64% of the stock is owned by institutional investors.

Design Therapeutics Price Performance

Shares of NASDAQ:DSGN opened at $11.93 on Thursday. Design Therapeutics, Inc. has a 1-year low of $3.33 and a 1-year high of $17.25. The business has a fifty day moving average price of $12.27 and a 200-day moving average price of $10.80. The company has a market capitalization of $745.15 million, a PE ratio of -9.94 and a beta of 1.63.

Design Therapeutics (NASDAQ:DSGN) last issued its earnings results on Tuesday, April 28th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.07. On average, sell-side analysts anticipate that Design Therapeutics, Inc. will post -1.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DSGN. Jefferies Financial Group began coverage on Design Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $15.00 price objective on the stock. Oppenheimer lifted their price objective on Design Therapeutics from $18.00 to $21.00 and gave the company an “outperform” rating in a research report on Monday, May 4th. Wall Street Zen raised shares of Design Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Royal Bank Of Canada lifted their price target on shares of Design Therapeutics from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Design Therapeutics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.